OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, February 17th

2/17/2010 11:49 AM

Penny Stocks by: OTC Picks

Buy HDUP Online for $0. Trade stocks for free on Zecco.com.

OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, February 17th HDUP, MFLI, BMGP, XPGH, GELV, CVM, SGTI, FKWL, MEXP, CYCC, DKAM Our Stocks to Watch today include HeadsUp Entertainment International Inc.

(OTC: HDUP), Muscle Flex Inc. (OTC: MFLI), Biomagnetics Diagnostics Corp.

(OTC: BMGP), XcelPlus Global Holdings Inc. (OTC: XPGH), Green Energy Live Inc. (OTCBB: GELV), CEL-SCI Corp. (NYSE Amex: CVM), Shengtai Pharmaceutical Inc. (OTCBB: SGTI), Franklin Wireless Corp. (OTCBB: FKWL), Marine Exploration Inc. (OTCBB: MEXP), Cyclacel Pharmaceuticals Inc. (Nasdaq:

CYCC) and Drinks Americas Holdings Ltd. (OTCBB: DKAM).

Visit http://otcpicknews.com/emailmarketer/link.phpM940&N6&L1&F=T to register for our Daily Market Movers Digest Newsletter and Email Stock Watch Alerts.

HEADSUP ENTERTAINMENT INTERNATIONAL (OTC: HDUP) "Up 9.09% in morning trading" Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L39&F=T Company Profile:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L43&F=T HeadsUp Entertainment International Inc. is a global media and entertainment company engaged in the creation of branded entertainment through the development, production and marketing of televised programming based on poker and other entertainment themes. For more information see the Company`s websites www.headsupentertainment.com and www.canadianpokertour.tv.

HDUP News:

February 17 - Profit, Party and Play on the Canadian Poker Tour and World Poker Showdown`s Super Cruise HeadsUp Entertainment International Inc. (OTC: HDUP) reports that its poker tourism business unit is witnessing a tremendous response to the launch of its first Poker Super Cruise. This event was designed and launched between the Canadian Poker Tour (CPT), HeadsUp`s main poker brand and The World Poker Showdown, a Company which has a strategic marketing alliance with the CPT and is in the due diligence phase of an impending acquisition by the Company.

The cruise takes place April 25 - May 2, 2010, departing Port Canaveral, Florida with ports of call in the Bahamas, St. Thomas and St. Maarten.

Hosted aboard Royal Caribbean Cruise Lines "Freedom of the Seas" this event looks to be this year`s premier poker event aboard the high seas featuring player friendly formats and structures in the daily poker tournaments designed by one of the world`s foremost tournament directors, Jimmy Miller.

The 7 day event will feature 10 poker tournaments with most buy in`s ranging from $150 to $500 and a $2700 Deep Stack Main Event. Online satellites are currently running on 888 Poker and Spotlight Poker where players can qualify to win travel, buy in`s and their cruise packages for as low as $3. All satellites guarantee a package creating excellent value for players to compete for.

This event will feature some incredible "poker life experiences" that HeadsUp and the CPT have become known for. Players will be able to mingle, meet, play and party with poker superstar Lacey Jones. Lacey was recently voted the "hottest girl in poker" and has recently signed a deal to be the new "face of the CPT" in Canada. Lacey will be in Calgary, Alberta February 25-28 at Cash Casino`s Winter Freeze Out promoting the cruise and the nearly 600 CPT events across the country scheduled this year. Players will also be able to meet Canadian Poker Player magazines CPT girl of the month Amanda Hellmer who is making the trek from Red Deer, Alberta to deal both tournaments and cash games in the exclusive poker room aboard the ship.

Adding to the experience, players can meet, play and party with World Poker Showdown Founder Herb Van Dyke as well as CPT President and CEO Kelly B.

Kellner.

"We are very happy with the response from players around the world as we have already seen bookings from 13 countries which always makes these events amazing," stated WPS Founder Herb Van Dyke. "We have held 5 cruises to date and this looks to be the best yet, as the Canadian contingent always adds excitement to the mix!" A number of categories aboard the ship are already sold out and space is filling up quickly in all of the events. More details can be found at www.canadianpokertour.tv or www.worldpokershowdown.com as well as the exclusive travel partner for the event CI Travel. They can be contacted directly at 1-800-627-8000.

HeadsUp has worked diligently over the past 2 years to build the poker tourism business unit within the organization. With successful events in Costa Rica, the Dominican Republic and Canadian Invasion last summer in Las Vegas at the Hard Rock Hotel and Casino`s Mega Stack Showdown, we are able to offer tremendous packages to our members. These events allow the Company to monetize its player base in a new way as 100% of the tournament fees and rake from cash games go directly to the bottom line. "We become the house for a week on this cruise", commented CPT President and CEO Kelly B.

Kellner. "We can ensure fairness, proper structures and an infrastructure designed by players for players. I look to this division of our Company to add substantial results to our profitability in 2010." This event will also be feature innovative television coverage on the Company`s online poker television network, www.canadianpokerplayer.tv which is set to launch this March. Incorporating new media delivery solutions and providing our sponsors with an all encompassing package, revenues are increasing exponentially and the substantial investments made over the past 5 years are now reaping the rewards they were designed to.

"I encourage everyone to book their package as soon as possible as this is an event not to be shut out of," stated Kellner. "Whether looking at our company as a potential investor, player or sponsor, I can assure you that the HeadsUp team is proud of our business model and the future is looking very bright." MUSCLE FLEX INCORPORATED (OTC: MFLI) Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L0&F=T Company Profile:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L2&F=T Muscle Flex Inc. brings new products to market using direct response TV infomercials specializing in the health, fitness, wellness and hygiene sectors. As well, Muscle Flex Inc. develops and creates general television content for network and cable television distribution. Muscle Flex`s corporate strategy is to develop new and innovative products for sale and distribution via its proprietary direct response marketing system and the creation of television media and shows for general network and cable broadcast.

MFLI News:

February 17 - Muscle Flex Inc. Cancels 5,043,750 Common Shares Muscle Flex Inc. (OTC: MFLI) announced that it has cancelled 5,043,750 shares of its common stock. The share cancellation is effective as of February 17, 2010.

On February 10, 2010, Muscle Flex Inc. announced the cancellation of 5,325,000 shares of its common stock for a combined total of 10,368,750 common shares. The share cancellation is in regards to a transaction from 2008 that was not concluded.

February 16 - Muscle Flex Provides Revenue Model for The Complete Package and Files Trademark Application with the USPTO Muscle Flex Inc. (OTC: MFLI) announced that it has submitted a trademark application for The Complete Package, a new reality television show that merges Victorias Secret style and attitude with The Apprentice business savvy. In addition, Muscle Flex Inc. is providing a macro description of The Complete Package revenue model.

The Complete Package, was created by Danny Alex, CEO of Muscle Flex, Inc. and is being filmed and developed with its partners TLK Fusion and Wesley Morris Entertainment. An open casting call for the pilot and opening episode is taking place Saturday, February 27, at 8:00am at HD Vision Broadcast Center in Studio City, California. The Complete Package welcomes all women with a pulse to participate in its edgy, just-when-you-thought-you-had-seen-it-all competition.

The Revenue Model The Complete Package The revenue model for The Complete Package is revenue that is comprised from the actual airing of the show for national broadcast as well as product placements, merchandising and cast appearances. Television shows generate revenue through third party companies and organizations purchasing advertising time during the airing of the broadcast. The revenue generated by advertisers is ultimately dependent on the popularity of the show based on viewership, and to a varying degree, the time slot. The distribution of the advertising revenue between parties (TV show owners and the Network) varies greatly from show to show as each television show is comprised of a number of factors that determines the revenue distribution of this revenue.

Muscle Flex, along with its partners, are developing The Complete Package in a way that allows for maximizing this revenue stream while providing full benefit and profitability with any network partner.

Product Placement Product placement revenue is a revenue stream that is generated by The Complete Package utilizing large corporate brands within the content of the program. This can come in a number of different forms given the content of any given episode however, product placement provides the advertiser the potential for significant brand awareness which can be much more effective compared to traditional advertising when featured within the story-line of a Complete Package episode. Muscle Flexs partner, TLK Fusion, is considered one of the leading product placement companies in Los Angeles and has extensive experience in developing brand awareness through value added product placements. Some of their media partners include; dick clark productions, Paramount Studios, CBS Radio, CBS Outdoors and Island Def Jam Records.

Merchandising A significant part to the revenue model for The Complete Package is the development of multiple merchandising offerings. The potential for developing additional revenue from merchandising of products is one that can be developed in a number of different product categories. These opportunities would be ongoing and limited by the imagination and success of the show.

Appearances As with any television show, intellectual property is developed by the personalities that make up the content of the show. Each season will have 10 new polarizing female personalities as well as the regular cast headed up by Muscle Flex CEO, Danny Alex. For an extended period of time, The Complete Package is in a position to monetize the personalities that it develops through appearances, promotional activities and product representations.

The revenue model of The Complete Package is ultimately dependent upon the specifics of any third party television network agreement and Muscle Flex Inc. shall provide investors with additional information upon a network agreement being finalized.

The Complete Package The Complete Package is searching for the new face and image of Muscle Flex for one season (http://otcpicknews.com/emailmarketer/link.phpM940&N6&L59&F=T).

What will the winning contestant receive The whole Hollywood experience! A contract representing Muscle Flex in advertising, red carpets and other public appearances, photo shoots, special promotions, corporate events as well as giving their smarts in the boardroom.

The 10-episode series will incorporate all of the drama, humor and the unexpected that comes when women compete. How does a beautiful woman get prepared for the opportunity of a lifetime What decisions go into make-up, hair, wardrobe, and attitude to standout from the rest What interaction takes place when theyre living with the competition Whos their friend and whos their enemy Thousands of women in all shapes and sizes are expected to participate for a chance at winning the title. The winner will be selected on the following criteria: Beauty, Business Smarts, Fitness, Fashion Sense, Intellect, Sex Appeal, Confidence, Spirit and Heart. The judging line-up will feature Danny Alex with his fellow celebrity judges.

Danny Alex states: Who is The Complete Package This show will redefine what sexy is in America and we are looking for all of it! This is a 24/7 competition never out of the eye of the camera. Special features in the show will include fashion couture on-a-budget, a swimsuit contest, perseverance, endurance, fitness, sales and business acumen, public appearances, and getting real in the must see and hear Truth Booth. Each week one contestant will be eliminated until only one winner stands in the spotlight.

The audience will also get to follow Dannys day-to-day business operations, the building of his brand and the interaction between his Muscle Flex staff and the contestants in a Beverly Hills, 90210 setting.

BIOMAGNETICS DIAGNOSTICS CORPORATION (OTC: BMGP) "Up 14.29% in morning trading" Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L2&F=T Company Profile:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L5&F=T Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company`s revolutionary diagnostic systems, which are based on advanced magnetics, test for any viral or bacterial disease using any body fluid. The Company`s technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test. The HTS-MTP platform is designed to detect the actual virus and viral load in body fluids and not just simply screen for the presence of viral antibodies.

BMGP News:

February 10 - Biomagnetics to Accelerate Availability of the World`s First Integrated Optical Biosensor for Malaria, Cholera, TB and HIV/AIDS Diagnosis Biomagnetics Diagnostics Corp. (OTC: BMGP), a developer of revolutionary diagnostic systems and technology for malaria, HIV/AIDS, hepatitis, tuberculosis and detection, announced today the implementation of a program to accelerate the availability of the world`s first Integrated Optical BioSensor (IOBS) platform. The Company is currently reviewing research and manufacturing partnerships to develop simple to replicate bench top versions of the IOBS platform on which single pathogen or multiple pathogen testing assay cartridges can be developed. This strategy is expected to significantly accelerate the availability of this life and cost saving technology.

The Companys initial strategy was to fully produce the handheld version of the IOBS platform and to then use that platform to develop all of the many different types of pathogen testing assay cartridges. By taking a slightly different direction and developing desktop versions of the IOBS platform, which can be produced more quickly, the Company will be able to develop the single test assay cartridges for malaria, cholera, human tuberculosis, bovine tuberculosis and HIV/AIDS in parallel to the production of the handheld units. This approach will significantly reduce time-to-market and make this important technology available to the world much sooner and will allow the corporation to accelerate its revenue growth rate.

It is important for us to accelerate assay test cartridge development as we are currently scheduling our malaria clinical trial with one of the most prestigious malaria research institutions in India with additional trials being organized in Kenya and Mexico, commented Clayton Hardman, CEO of Biomagnetics Diagnostics Corp. We are very anxious to begin demonstrating this technology in real world settings as we believe we will be able to lower the cost of malaria, tuberculosis, cholera and HIV/AIDS testing to unprecedented levels while at the same time reducing the time it takes to receive results from days or hours to a matter of a few minutes.

While we believe the production of this device will yield significant returns for our shareholders, and this is clearly an important priority, we have never lost sight of the fact that there are tens of thousands of lives we may be able to save through our important endeavors in this area.

XCELPLUS GLOBAL HOLDINGS INCORPORATED (OTC: XPGH) Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L29&F=T Company Profile:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L32&F=T Xcelplus Global Holdings, Inc., a development stage company, develops and produces federally compliant biomass based renewable fuels for the light, medium, and heavy industries. Its product lines include synthetic fuel oils, biomass release agent, and btu enhancer. The company holds various technologies and licenses them for manufacturing and distribution. Its technologies include digiflex, lubrilon, alternative energy centers, E85 flex lube centers, diesenol, glycoal, and glyclene. The company is headquartered in Dothan, Alabama.

XPGH News:

February 16 - Carbon-credit Requirements Stimulate European Sales Opportunities For XcelPlus Global Holdings` Industrial Biofuel European signatories of the Kyoto Protocols have opened up new sales opportunities for the industrial biofuels produced by XcelPlus Global Holdings, Inc. (OTC: XPGH), and the company reports it is in active negotiation with several prospects. "A Perfect Storm of market conditions exists within countries that signed the Kyoto Protocols, and companies that need to amass carbon credits are calling us," said J. Michael Parsons, president and CEO of XcelPlus Global Holdings Inc.

"Europe is ideal for us," Parsons stated. "Because the price for all petroleum fuels is much higher in Europe to start with, we can be a very cost-effective replacement for No. 2 oil over there, without government subsidies. And because our products are not for `road use,` we are unaffected by the normal European tariffs on biodiesel." Industrial biofuels from XcelPlus Global meet ASTM standards for Biomass Renewable Diesel Fuel Oil for Power Generation, allowing them to replace No. 2 industrial fuel oil and qualify the user to receive carbon credits.

Although carbon credits are not an issue for companies operating in the U.S., carbon offset requirements and pricing conditions for petroleum-based fuel oil allow XcelPlus fuels to be both competitive and profitable as a No. 2 replacement without government subsidies, Parsons stressed. "Our company is entering a new era where it won`t be dependent on government subsidies to create markets," he stated.

GREEN ENERGY LIVE INCORPORATED (OTCBB: GELV) Detailed Quote: www.otcpicks.com/quotes/GELV.php Company Profile:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L7&F=T Green Energy Live Inc. is engaged in developing sustainable biomass-to-energy conversion technology to meet a critical need for the nation`s $154 billion livestock industry. The company plans to use its proprietary gasification technology for the development of highly innovative, on-site manure-to-electricity conversion systems to enable livestock farmers and ranchers to convert their animal waste into clean, renewable energy.

GELV News:

February 4 - Green Energy Live Expands Operations to Accommodate Growth Green Energy Live Inc. (OTCBB: GELV), a clean energy company engaged in developing sustainable biomass-to-energy conversion solutions for the U.S.

livestock industry, is pleased to announce that the company has moved into new offices to accommodate its growing business. With its expanded team and new corporate headquarters Green Energy Live is focusing on the development of on-site manure to energy converters for farmers and ranchers, pursuing acquisitions of clean energy companies and technologies, and achieving sales and revenue increases through its wholly owned Comanche Livestock Exchange subsidiary.

Green Energy Live has moved out of a smaller executive office suite and into 2,500 square feet of newly leased office space in Wyoming, Michigan.

The company is bringing together its executive, accounting and business development staff members to accommodate its plans for expansion.

The company has also added to its workforce. Green Energy Live has hired a seasoned Manager of Special Projects to identify green energy companies and technologies for potential acquisition, manage any upcoming acquisitions, align financial functions and reporting, provide support for Comanche`s business, and manage marketing activities. A highly qualified in house accounting staff member has also been hired to support financial and reporting functions.

Comanche Livestock Exchange, a wholly owned subsidiary of Green Energy Live, generated an 18% increase in revenue and a 6% increase in net income in third quarter 2009. The company is a profitable livestock auction and hauling services provider with a 60 year operating history. Green Energy Live anticipates reporting on fourth quarter performance later this month.

Karen Clark, President/CEO of Green Energy Live, commented: "We are pleased to announce that we have officially outgrown our office space. With the expansion into new offices, addition of exceptional new team members and the identification of new opportunities to grow our business this is a very exciting time for Green Energy Live. We are balancing expansion activities with a keen eye on the bottom line, keeping overhead and expenses low while facilitating further growth." CEL-SCI CORPORATION (AMEX: CVM) "Up 21.37% in morning trading" Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L31&F=T CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. Its lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company is also developing CEL-1000, which is derived from a pre-clinical technology called Ligand Epitope Antigen Presentation System to stimulate the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer; and CEL-2000 for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.

CVM News:

February 17 - CEL-SCI Corporation Releases Letter to Shareholders The following letter is being released by CEL-SCI Corporation (NYSE AMEX:

CVM) to its shareholders:

Dear Fellow Shareholders, We are pleased to report to you that the past 12 months have put CEL-SCI in the best position ever. During this difficult time we were able to complete and validate the manufacturing facility for our cancer drug Multikine, a critical step before being able to manufacture Multikine for the Phase III clinical trial. We are developing a novel investigational treatment for H1N1 hospitalized patients and were able to take this investigational treatment into a clinical trial at Johns Hopkins University in record time. At the same time we also raised over $40 million in new capital and added a new marketing partner for Multikine in South Africa.

Unlike the existing partners, Teva Pharmaceuticals and Orient Europharma, who will be participating in the Phase III study in Israel and parts of Asia, Byron Pharma will only be focused on marketing and will not participate in the Phase III trial. With the manufacturing facility completed and $36 million in the bank, we are now able to start our Phase III trial for Multikine in advanced primary head and neck cancer.

The Phase III study seeks to build on the excellent data we derived from our Phase II study of Multikine. The data were published in several leading peer-reviewed cancer journals. What is so impressive is that the data were derived from a well-controlled, blinded pathology study which used tumor samples from patients treated with Multikine in the last Phase II head and neck cancer study, as well as matched tumor samples from head and neck cancer patients not treated with Multikine. The pathologists who participated in this study were blinded to the study and to the patients` clinical outcome. The results were so impressive that we were able to present the pathology tumor data at ASCO (American Society of Clinical Oncology) and have them published in the very prestigious peer-reviewed Journal of Clinical Oncology. The promising overall survival data were presented in an oral presentation at the International Conference of Oral Oncology, Amsterdam, 2007 and were published in the peer-reviewed Journal of Oral Oncology.

The pathology data showed clear clinical benefit to the Multikine-treated patients and suggested that overall patient survival should be improved with Multikine administration. The longer-term follow-up of the Multikine-treated patients showed that overall survival indeed was improved in these patients. To avoid any bias, the Multikine survival data in the Phase II trial was compared to the results of all peer reviewed published data available at that time (39 publications). As time progressed and more publications became available, we updated this comparison and included all of the more recently published peer-reviewed data from these publications (a total of 55 publications). Our findings of the impact of Multikine administration on the overall survival benefit for these patients still held true.

The safety and efficacy data for Multikine were reviewed by different regulatory agencies, including the US Food and Drug Administration (FDA), prior to giving CEL-SCI clearance to proceed with a global Phase III for Multikine in head and neck cancer. The open-label, randomized, controlled Phase III study of Multikine in patients with head and neck cancer is designed to demonstrate that Multikine administration to these patients yields an overall survival benefit. The study will enroll about 800 patients worldwide.

While we already showed a 33% improvement in overall survival in Phase II, we only need 10% in the Phase III study to meet our primary endpoint. We have added multiple years to the development process of Multikine in order to build a Multikine dedicated manufacturing facility near Baltimore. This was done at the advice of the regulatory agencies and as an additional step of risk mitigation since the use of a contract manufacturer adds a great deal of risk in maintaining quality control. We have taken every conceivable risk mitigation step to increase the probability of a favorable outcome for this breakthrough product.

On the other hand, recognizing that every drug development carries risk, we have attempted to set the study up to become a huge financial success for the shareholders. Assuming we are right, Multikine will become the first treatment to be used in the treatment of nearly all newly diagnosed head and neck cancer patients (about 650,000 patients worldwide). It will become part of the new standard of care. That means that doctors will be advised to use Multikine as the first treatment for head and neck cancer patients. Insurance companies and governments should reimburse the use of Multikine because it will be cost effective and because they pay for the current standard of care treatments, surgery, radiation and chemotherapy.

This would translate into billions of dollars in sales while at the same time helping to save lives. Usually such successes are shared with a big pharmaceutical partner and the upside for the small company`s shareholders is limited. In the case of CEL-SCI, shareholders still control most of the upside as CEL-SCI still owns all of the major marketing rights. Very few companies find themselves in this advantageous position as they enter Phase III. A major drug for a large unmet medical need, unencumbered by a partnership in the biggest markets! We feel that we have created a great situation and opportunity for our shareholders with the development of Multikine as a first-line treatment for cancer. We have a great team and, for the first time, the funds to execute our plans.

We have also advanced with the very rapid development of our investigational treatment for H1N1 hospitalized patients. This treatment is based on our LEAPS technology which allows us to direct an immune response outcome. During the height of the H1N1 wave in the fall of 2009 we worked as fast as possible to move into clinical trials for this new investigational treatment of hospitalized H1N1 patients, as these patients are at serious risk of dying. We started a study at the Johns Hopkins University School of Medicine in November 2009. This study needs to enroll 20 H1N1 hospitalized patients and 20 healthy individuals as the control group. We are waiting for Johns Hopkins to complete the study. Patient enrollment is completely dependent on patient availability of H1N1 hospitalized patients at Johns Hopkins.

Currently H1N1 does not appear to be a big problem in the US. However, it continues to infect and kill patients in other places around the world.

Some people think that H1N1 is gone, like Avian Flu and SARS appear to be gone. H1N1 is different though. H1N1 has already infected different populations all over the world. It is the first flu virus that can infect humans throughout all four seasons. As a flu virus it undergoes rapid mutations. As such, similar to the normal seasonal flu, we are likely to see H1N1 reappear in a mutated form. Our greatest fear is that it might pick up pieces of genetic information from the more deadly Avian flu or the Spanish flu and become an easy to transmit life threatening virus. To address this possibility, CEL-SCI scientists have included in the LEAPS-H1N1 investigational treatment non-changing parts of the H1N1 virus, as well as non-changing parts of the Avian flu and Spanish flu viruses. We will continue with the development of this investigational treatment because we expect it to become increasingly important in the future.

As we are now entering the home stretch for Multikine, many people will have opinions about its prospects, favorable and unfavorable. While many lives could depend on the success of the Multikine Phase III study, a significant amount of money is at stake as well. You may ask us to respond to articles written about CEL-SCI on the internet. We believe it is important to set the record straight, and will try to respond, where practical, to credible providers of information in order to ensure that shareholders have the correct information. However, we will not respond to writers of dubious credibility, people who clearly have an agenda of bashing and who attempt to distort or obfuscate the facts. We hope that shareholders will make their decision on the merits of the drugs and the many peer reviewed scientific publications, not on what is said by bloggers with an agenda, bashers and other dubious characters. Remember, many of them have an agenda quite different from yours and ours.

While success is never a certainty, we believe that we have already overcome many obstacles. We have positioned CEL-SCI and its investors to benefit from an opportunity that few small biotechnology companies ever get. The ability to conduct a pivotal clinical study in an area which represents a large unmet medical need, where the company maintains a substantial upside! A chance to develop a non-toxic cancer therapy! As always, we thank you for your support.

Sincerely, Geert Kersten Chief Executive Officer Maximilian de Clara President SHENGTAI PHAMRACEUTICALS (OTCBB: SGTI) Up 19.47% in morning trading Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L32&F=T Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the holding company for Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of glucose products, which include pharmaceutical grade glucose used for medical purposes, and glucose and cornstarch products for the food and beverage industry and for industrial production in China.

SGTI News:

February 16 - Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal Year 2010 Financial Results Shengtai Pharmaceutical, Inc. (OTCBB: SGTI) (``Shengtai`` or ``the Company``), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today reported financial results for the second quarter of fiscal 2010 ended December 31, 2009.

Second Quarter 2010 Financial Summary * Second quarter 2010 revenues totaled approximately $28.51 million, approximately $13.71 million or $92.7% increase compared to the same period last year.

* Second quarter 2010 gross margin is 15.68% compared to 13.48% same period last year.

* Second quarter had positive operating cash flow of approximately $8.73 million * Cash and restricted cash of approximately $17.08 million "The first quarter fiscal year 2010 brings our company back to profitable and creates a very good opening for fiscal year 2010. Our company continued this good opening and sales revenue had a steady increase in the second quarter fiscal year 2010. Our glucose revenue increased approximately 50% compared to the same period last year. Selling, general and administrative (SG&A) expenses for the three months ended December 31, 2009 were approximately $2.20 million, a decrease of $127,209 compared with the same period last year. Our improving financial results show that our strategies of controlling costs, improving product structure to create a higher gross profit products mix, and expanding market share in pharmaceutical glucose markets are successful," said Mr. Qingtai Liu, Shengtai Pharmaceutical`s CEO. "The competition in the last year was tough but we are proud that we survived the economic crisis and are on the right track to our goal of becoming the largest pharmaceutical glucose provider." Second Quarter Fiscal 2010 Financial Results Second quarter 2010 revenues were approximately $28.51 million, a 92.7% increase year-over-year compared to the approximately $14.80 million reported in the second quarter of fiscal 2009. Sales of glucose products totaled approximately $13.89 million during the second quarter as it accounted for 48.7% of sales. Cornstarch sales for the quarter totaled approximately $7.00 million or 24.6% of revenues. Sales of other products totaled approximately $7.62 million or 26.7% of revenues. The increase in sales revenue resulted from the increase of our export sales and domestic cornstarch and other products sales. Exporting sales revenue for the three months ended December 31, 2009 increased approximately 307% compared with the corresponding period in 2008. The increase is because with the recovery of the global economic crisis and with our exporting department reorganization in fiscal year 2009, the international demand of our glucose and protein powder products increased compared to the same period last year. Domestic sales for cornstarch and other products for the three months ended December 31, 2009 increased approximately 127% compared with the same period last year. The increase in domestic sales was because of the higher demand for cornstarch and increase in unit sales price for cornstarch.

Gross profit for the three months ended December 31, 2009 was approximately $4.47 million compared with approximately $1.99 million the same period last year. The increase in gross profits resulted from the increase in sales compared with the same period in 2008. Gross margin was 15.7%, a rise from 13.5% in the second quarter of fiscal 2009. The reasons for the increase in gross profit margin was because of decreased selling, general, and administrative expenses.

Selling, general and administrative (SG&A) expenses for the three months ended December 31, 2009 were approximately $2.20 million, a decrease of $127,209 compared with the same period last year. The decrease in our Selling, General and Administrative expenses was mainly the result of our efforts in controlling our costs. Especially we have controlled our professional expenses as a public company by lowering our legal, audit, and investment relationship expenses. We incurred $158,818 in non-cash stock option expenses for the three months ended December 31, 2009.

Second quarter 2010 net income was approximately $1.05 million or 5 cents per diluted share, compared to second quarter 2009 net loss of $473,887 or 2 cents per diluted share. The increase in net income was primarily due to the increase in our sales, decreased selling, general, and administrative expenses, and increase of other income.

Financial Condition As of December 31, 2009, Shengtai Pharmaceutical had cash and restricted cash totaling approximately $17.08 million. The Company generated approximately $8.73 million in positive cash flow from operations during the second quarter. The Company`s short-term loan totaled approximately $33.30 million and long-term debt totaled approximately $4.24 million. The Company`s total shareholders` equity increased to approximately $47.17 million.

Business Outlook Based on its current outlook, and existing and anticipated business conditions, Shengtai expects net income for fiscal year ending June 30, 2010 to be between 3 to 5 million.

"Looking forward, we see increased demand of our products and are confidant about our cash position," said Mr. Qingtai Liu, Shengtai Pharmaceutical`s CEO. "The Chinese government`s stimulus plan is taking effect. More medical clinics are built or going to be built. The new clinics increased the demand for our pharmaceutical glucose products. We remain our leading position in this field to provide approximately 40% of the China pharmaceutical market share. The oral glucose and the cornstarch market are recovering. Some companies in the cornstarch and oral glucose business did not survive during the world economic crisis while we reserved our cash and other resources. We now have the resources and capabilities to catch the recovered business. The exporting market is recovering as well.

Our reorganization of the exporting department last year also contributed to our success. In general, we are very confidant to welcome a profitable and growing fiscal year 2010 and 2011." FRANKLIN WIRELESS CORPORATION (OTCBB: FKWL) "Up 28.38% in morning trading" Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L9&F=T Franklin Wireless Corp. designs and sells wireless broadband high speed data communication products. It offers wireless broadband modules and modems. The company`s mobile broadband and data products include wireless USB modems, embedded modules, and stand-alone mobile broadband modems. Its products are used, with broadband high speed data service, to access wireless data communications networks using laptops, handheld, and desktop computers. The company`s products also enable its customers to send and receive email with large file attachments and play interactive games, as well as receive, send, and download high resolution picture, video, and music contents. Franklin Wireless markets its products through original equipment manufacturers and distributors, as well as directly to operators and end users. The company serves customers located in the United States, Caribbean, South America, and Africa. Franklin Wireless was founded in 2001 and is headquartered in San Diego, California.

FKWL News:

January 28 - Franklin Wireless Appoints Richard Walker as Vice President, Finance Franklin Wireless Corp. (OTCBB: FKWL) (www.franklinwireless.com), the market leader in dual-mode WiMAX/CDMA modems for 3G and 4G wireless broadband data communications, announced that it has appointed Richard ("Rick") Walker as Vice President, Finance.

"Franklin Wireless is fortunate to gain an executive of Rick Walker`s caliber to serve as our vice president of finance," said OC Kim, co-founder and president of Franklin Wireless. "Rick`s financial expertise and long history in our industry will bring significant value to our management team and help to chart the company`s course for future growth." Prior to joining Franklin Wireless, Walker was senior vice president and chief financial officer for Intercasting Corporation, where, among other achievements, he managed the financial and administrative efforts for a $12 million Series B round of funding and later the sale of the company to Good Technology.

Previously, Walker served as director of financial planning and analysis for Peregrine Systems, a $200 million publicly traded international software company. Earlier, he was vice president of finance for MP3.com, where he played a key role in the company`s initial public offering (IPO), raising $384 million, which at the time was the largest IPO ever for an independent Internet company. Prior to MP3.com, Walker was head of finance for a division of QUALCOMM and was a member of QUALCOMM`s original corporate financial planning group.

Walker earned a bachelor`s degree in business economics from the University of California, Santa Barbara, and an M.B.A. from the University of San Diego.

MARINE EXPLORATION INCORPORATED (OTC: MEXP) "Up 13.92% in morning trading" Detailed Quote: www.otcpicks.com/quotes/MEXP.php Marine Exploration, Inc., a development stage company, engages in marine treasure hunting expeditions. It involves in the exploration and recovery of deep-ocean shipwrecks, including the marketing, sale, and distribution of recovered artifacts, replicas, merchandise, and books through various retail and wholesale sales channels. The company was incorporated in 1996 as Jenkon International, Inc. and changed its name to Multimedia K.I.D., Inc. in 1999. Later, it changed its name to SYCO, Inc. in 2006; and to Marine Exploration, Inc. in 2007. The company is based in Denver, Colorado.

MEXP News:

February 12 - Marine Exploration Ready to Resume Salvage Operations; Authorities Authenticating Packing Seal from Sunken Wreck Which Could Considerably Increase Valuation of Treasure Marine Exploration, Inc. (OTCBB: MEXP) and its Joint Venture Partner Hispaniola Ventures, LLC, announces the RV Hispaniola is ready to resume salvage of the shipwreck at the North Coast site off the Dominican Republic. Bad weather, choppy seas, and poor visibility have delayed the continuation of treasure diving and the recon at another nearby proven site. Both wrecks can be worked concurrently using reef boats from the RV Hispaniola master vessel.

A packing seal discovered among the treasures has been sent to the authorities. Upon authentication, it will verify the name of the sunken ship and could considerably increase the valuation of the treasure found.

Burt D. Webber Jr., famed diver that in 1978 discovered the Concepcion in Dominican Republic waters, is currently the onsite Director of Operations aboard the RV Hispaniola treasure salvage vessel.

CYCLACEL PHARMACEUTICALS INCORPORATED (NASDAQ: CYCC) "Up 16.25% in morning trading" Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L14&F=T Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel`s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair Cream for radiation dermatitis, Numoisyn Liquid and Numoisyn Lozenges for xerostomia. Cyclacel`s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

CYCC News:

February 17 - New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel`s Seliciclib in Treating Breast Cancer Resistant to Hormone Therapy Seliciclib Kills Hormone Receptor Positive Breast Cancer Cells Resistant to Letrozole Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced that a newly published study demonstrates that the company`s seliciclib (CYC202 or R-roscovitine), an orally available inhibitor of multiple cyclin-dependent kinases (CDKs), reversed resistance to the aromatase inhibitor letrozole (Femara) and killed hormone receptor positive breast cancer cells that had become insensitive to the effects of letrozole. The new study was published in the current edition of Clinical Cancer Research, a journal of the American Association for Cancer Research. Seliciclib is currently in Phase 2 clinical trials for non-small cell lung cancer and nasopharyngeal cancer.

"Resistance to aromatase inhibitors, such as letrozole, is a major challenge for the long-term management of hormone receptor positive breast cancer," said Professor David Glover, Ph.D., Cyclacel`s Chief Scientist.

"The data published in Clinical Cancer Research are encouraging as they show that seliciclib can kill resistant breast cancer cells by targeting a form of cyclin E that is a major cause of the resistance. This is further evidence that seliciclib`s unique mechanism of action can be effective against certain cancer cells, such as breast and lung cancer, that fail to respond to standard cancer treatments." Approximately 3 out of 4 women suffering from breast cancer after menopause have cancers that express the hormonal receptors for estrogen and progesterone and are offered treatment with aromatase inhibitor drugs including letrozole. Letrozole treatment reduces the risk of early metastasis in women with estrogen receptorpositive breast cancer.

Letrozole is believed to interact with a natural CDK inhibitor p27 which in turns regulates the activity of the CDK2/cyclin E complex. Over time, breast cancer cells develop resistance to letrozole and the therapy becomes ineffective.

Researchers from The University of Texas M.D. Anderson Cancer Center led by Khandan Keyomarsi, Ph.D., professor in the Department of Experimental Radiation Oncology, found that a key cause of resistance to letrozole is overexpression of the low molecular weight form of cyclin E, which also predicted for lower overall survival and higher chance of cancer recurrence after aromatase inhibitor treatment. However, after they treated letrozole-resistant breast cancer cells with seliciclib, a CDK2/cyclin E inhibitor, the resistant cancer cells were killed. The researchers concluded that their data support clinical investigation of CDK inhibitors such as seliciclib as targeted therapy in a specific patient population of postmenopausal women with hormone receptorpositive, low molecular weight cyclin E expressing breast cancer. Citation: Akli S., et. al., Clinical Cancer Research, 2010 16:4:117990.

ABOUT SELICICLIB Seliciclib is an orally available molecule that selectively inhibits multiple cyclin-dependent kinase or CDK targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control. Seliciclib has been administered to approximately 450 patients in Phase 1 and Phase 2 trials. It is currently being evaluated in the APPRAISE trial, a Phase 2b randomized, double-blinded, placebo-controlled study, as a treatment in patients with non-small cell lung cancer (NSCLC) who failed at least two prior therapies and in a randomized Phase 2 study as a single agent in patients with nasopharyngeal cancer.

The APPRAISE trial is assessing the efficacy and safety of single-agent seliciclib as a third, fourth or fifth line treatment in patients with NSCLC. The study is using a randomized discontinuation design with a primary endpoint of progression free survival.

ABOUT CDK2/CYCLIN E Cyclin E, a cell cycle protein, binds to its partner enzyme CDK2, a cyclin-dependent kinase, forming a complex. The CDK2/cyclin E complex plays a key role in regulating the progression of cells through the four stages of the cell cycle and the two cell cycle arrest checkpoints where cells are checked for damage to their DNA before they divide. Unlike normal cells, cancer cells modify cyclin E to a low molecular weight form which has been associated with genomic instability, uncontrolled proliferation and overtime the evolution of resistance to cancer treatments.

ABOUT LETROZOLE Letrozole is an aromatase inhibitor indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer and the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

DRINKS AMERICAS HOLDINGS LIMITED (OTCBB: DKAM) "Up 15.00% in morning trading" Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N6&L09&F=T Drinks Americas develops, owns, markets, and nationally distributes alcoholic and non-alcoholic premium beverages associated with renowned icon celebrities. Drinks Americas` portfolio of premium alcoholic beverages includes Trump Super Premium Vodka and Willie Nelson`s Old Whiskey River Bourbon. The Company`s non-alcoholic brands include the distribution of Paul Newman`s Own Lightly Sparkling Fruit Juice Drinks and Flavored Waters.

The company also has a partnership with Universal Musics Interscope, Geffen, A&M Records to jointly develop and launch beverage products. Other products owned and distributed by Drinks Americas include award-winning Damiana Liqueur and Aguila Tequila from Mexico, Cohete Rum Guarana from Panama, and Rheingold Beer. Damiana, Old Whiskey River, Aguila Tequila and Cohete Rum are Gold and Silver Medal award winners respectively from the International Beverage Tasting Institute and the San Francisco International Wine and Spirits Competition. Drinks Americas was founded in 2004 by J. Patrick Kenny, a leading expert in beverage sales and marketing.

Mr. Kenny developed his industry expertise in a variety of management positions at the world`s leading beverage companies, including Joseph E.

Seagram and Sons and The Coca-Cola Company. He has also acted as advisor to several Fortune 500 beverage marketing companies, and has participated in several beverage industry transactions.

DKAM News:

February 17 - Drinks Americas Offers Guidance for Third Quarter 2010 and Review of Venture with Mexcor International Wine and Spirits; Third Quarter Revenue Growth Up $385,000 Over Second Quarter Company Previews Substantial Debt and Overhead Reduction Drinks Americas Holdings, Ltd. (OTCBB: DKAM), a leading owner, developer and marketer of premium beverages associated with renowned icons, reiterated that it will hold an earnings call on February 17, 2010 in order to review quarterly results from the second quarter 2010, and to offer a preliminary view of results for the third quarter 2010. The Company will also discuss its reduction of debt and overhead, as well as the recent material developments in its venture with Mexcor International Wine and Spirits.

As previously reported, due to capital constraints, the Company`s second quarter shipments and resulting revenue were only $15,000. In the third quarter 2010 ended January 31, 2010, the Company shipped and sold approximately $400,250 in product.

As a result of various negotiations, the Company has reduced its payables and short term debt, which will be reflected in third quarter reporting. As a result of the reconfiguration of the Company`s business model, Drinks` annual overhead will be reduced from an historical run rate of more than $4.8 million annually to approximately $1.2 million annually.

The Company recently announced a venture with Mexcor International Wine and Spirits to accelerate the production and distribution of its products, which will be discussed during the Feb 17th call. Drinks will publish a shareholder letter that will be posted on www.drinksamericas.com following the call describing this new venture.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N6&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N6&L=8&F=T.

Disclosure: OTCPicks.com has been compensated seven thousand five hundred dollars from company for this current MFLI advertising and promotional program. OTCPicks.com has been compensated four thousand dollars by a third party and seventy one thousand restricted rule 144 shares by the company for a current 30-day BMGP advertising and promotional program. OTCPicks.com has been previously compensated ten thousand dollars by a third party for past 2009 BMGP advertising and promotional services. OTCPicks.com has been compensated four thousand dollars by a third party for XPGH advertising and promotional services. OTCPicks.com has been compensated four thousand dollars by a third party for a previous one-week GELV advertising and promotional program. OTCPicks.com is currently being compensated five thousand dollars from BlueWave Advisors for GELV advertising and promotion.

OTCPicks.com has received forty thousand free trading shares from a third party for MEXP advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has not been compensated by any of the companies covered in this release. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php . The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor`s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company`s ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

Disclaimer: http://www.otcpicks.com/disclaimer.htm

Disclosure Details: http://www.otcpicks.com/disclosure-details.htm

CONTACT: Brian Dean, Publisher, OTCPicks.com
Tel: +1 972 546 3740
EMail : publisher@otcpicks.com

See OTC Picks's website for full disclaimer. OTC Picks may have received compensation for stock picks.